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History 
A 69-year-old gentleman lost consciousness with a glucose of 2.4mmol/L, having experienced 
recurrent daytime hypoglycaemic symptoms for at least five years, and latterly overnight. He suffered 
from hypertension, benign prostatic hypertrophy and hypogonadotrophic hypogonadism. There was 
no personal or family history of diabetes or endocrinopathy. He had never worked in healthcare. 
Investigations 
Hypoglycaemia (glucose 1.8 mmol/L) was confirmed during a supervised fast. Insulin and c-peptide 
were inappropriately detectable, consistent with endogenous hyperinsulinaemic hypoglycaemia 
(Figure 1A). 
Cross-sectional imaging (Figure 1B) revealed a large left supra-renal mass invading the left renal vein 
and inferior vena cava and an enlarged coeliac trunk lymph node. These findings were unexpected 
and prompted further investigation. 
Urine normetadrenaline was elevated. Chromogranin A and B were elevated; the remaining gut 
peptides were unremarkable. Adrenal androgens were normal and urine cortisol metabolites were 
consistent with physiological stress. Both the supra-renal mass and lymph node were 18FDG-avid. 
Additionally, there was diffuse abnormal FDG-uptake throughout the pancreas without an anatomical 
correlate. The supra-renal mass was MIBG-avid (Figure 1D). 
These results are consistent with a tumour of neuroendocrine origin. Given the diffuse pancreatic 
FDG-avidity, we postulated that tumoural production of a secretagogue was stimulating pancreatic 
insulin release. Analysis of incretin hormones during hypoglycaemia revealed a markedly and 
inappropriately elevated GLP-1 (Figure 1C). Neurotensin (co-secreted with GLP-1 from the gut) was 
undetectable, suggesting that GLP-1 production was ectopic. Genetic testing for a 
phaeochromocytoma-predisposing mutation was negative. 
Management and progress 
Hypoglycaemia responded to somatostatin analogue therapy. Doxazosin was added for blood 
pressure control. Surgery was scheduled but rapid disease progression occurred and chemotherapy 
was initiated. Disease stability was initially achieved following four cycles of cisplatin/carboplatin and 
etoposide, however three months later abdominal pain returned and imaging confirmed disease 
progression. Temozolamide was commenced and a partial response was observed after six cycles. 
One year following diagnosis he remains independent with few symptoms. 
Discussion 
Hypoglycaemia is an uncommon but important cause of transient loss of consciousness in non-
diabetic patients. Diagnosis requires assessment of blood glucose, insulin and c-peptide during 
symptomatic hypoglycaemia in order to determine aetiology. Inappropriately detectable insulin and c-
peptide, as here, suggests endogenous hyperinsulinaemic hypoglycaemia, most commonly due to a 
pancreatic insulinoma. 
Imaging findings in this case were unexpected and demonstrated a malignant, locally invasive adrenal 
lesion with associated lymphadenopathy. Biochemistry and functional imaging were supportive of the 
diagnosis of phaeochromocytoma. 
Phaeochromocytomas are rare but life-threatening neuroendocrine tumours (NETs) of the adrenal 
medulla. They frequently cause hyperglycaemia due to a combination of increased hepatic glucose 
production and inhibition of glucose uptake and insulin release. Hypoglycaemia occurring immediately 
following resection has been widely observed (Chen et al. 2014) but preoperative hypoglycaemia is 
rare and is often mediated by IGF-2 and not insulin (Gorden et al. 1981). 
Two phaeochromocytomas with insulin-mediated hypoglycaemia that fulfil Whipple’s triad have been 
reported. In one (Uysal et al. 2007), tumour immunohistochemistry was positive for insulin, suggesting 
direct insulin secretion. In the other (Frankton et al. 2009), it was negative and massive insulin release 
due to pancreatic haemorrhage was the postulated mechanism. 
In our case, diffuse pancreatic FDG-uptake prompted assessment of the incretin hormones. GLP-1 
was inappropriately elevated at the time of hypoglycaemia, to a magnitude similar to that seen during 
hypoglycaemia following gastric bypass surgery. An undetectable neurotensin confirmed ectopic 
GLP-1 secretion. GLP-1 mediated hypoglycaemia has previously been reported in association with 
ovarian (Todd et al. 2003) and pancreatic (Roberts et al. 2012) NETs. In both these cases, unlike 
ours, concurrent hyperglycaemia was also present due to secretion of somatostatin and glucagon 
respectively. 
This is the first report to our knowledge of hypoglycaemia due to a GLP-1 secreting 
phaeochromocytoma. 
Word count: 600 (600 limit) 
 
Learning Point for Clinicians’  
The accurate diagnosis of spontaneous hypoglycaemia requires a combination of clinical awareness 
and careful biochemical evaluation to determine aetiology. Further investigation and considerations 
are necessary if imaging findings are inconsistent with the most frequent responsible pathology. 
 
 
Figure Legend 
A – Glucose (black) and insulin (green) concentrations during a fast. The red line represents 
hypoglycaemia (plasma glucose 2.2 mmol/L). 
B – T2-weighted axial abdominal MRI showing the large left adrenal mass (yellow arrow) and the 
enlarged coeliac trunk lymph node (red arrow). 
C – Glucose (black) and GLP-1 (blue) concentrations during a fast. The red line represents 
hypoglycaemia as in figure A. 
D – I-123 MIBG scintigraphy demonstrating avidity in the left adrenal mass. 
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